Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short Interest

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 200,200 shares, a growth of 16.9% from the February 28th total of 171,200 shares. Based on an average daily volume of 96,600 shares, the […]

Related Keywords

,Corvus Pharmaceuticals ,Nasdaq ,Morgan Stanley ,Discovery Capital Management ,Institutional Trading Of Corvus Pharmaceuticals ,News Ratings For Corvus Pharmaceuticals Daily ,Corvus Pharmaceuticals Stock ,Corvus Pharmaceuticals Inc ,Get Rating ,Capital Management ,Sigma Advisers ,Two Sigma Investments ,Sigma Investments ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Stocks ,Options ,Put ,Call ,